SIBO and fatty liver: the circuit medicine splits in two, but the body never did

The bloating comes back. The liver doesn’t improve. That isn’t bad luck — it’s because no one has treated both conditions for what they actually are: two faces of the same dysfunction. Here is what the research shows, and what Chinese medicine adds that gastroenterology alone cannot offer.

GUT-LIVER AXIS · INTEGRATIVE MEDICINE · MILAN · LUGANO

Jasmine Angelique — TCM Practitioner, Certified Clinical Naturopath · Updated April 2026 · In-clinic: Milan & Lugano · Telemedicine worldwide

Key statistics

25–30%Estimated NAFLD prevalence in Italian adults

3×Higher SIBO prevalence in NAFLD patients vs. healthy controls

60%Of NAFLD+SIBO patients show increased intestinal permeability

18 RCTsClinical trials on acupuncture for NAFLD (2024 review)

The problem isn’t SIBO. It isn’t fatty liver. It’s the way we divide what the body never separated.

One of the most frustrating clinical patterns in integrative medicine is this: someone follows a SIBO protocol, improves for a few months, then relapses. Or they start a fatty liver programme, transaminases drop slightly, but the bloating, fatigue, and constipation remain exactly where they were.

And when the root goes untouched, the tree grows back the same way every time.

A decade of research on the gut-liver axis is unambiguous: molecules including LPS and PAMPs produced in the intestine reach the liver via the portal vein, condition its metabolism, and prepare the ground for steatosis. This is not functional medicine conjecture. It is documented pathophysiology.

The precise mechanics: where LPS originate and where they land

When bacteria proliferate in the small intestine — the wrong space, the wrong concentration — they alter the mucosa in a specific way: they reduce tight junction integrity between enterocytes, increase paracellular permeability, and allow bacterial lipopolysaccharides (LPS) to enter the portal circulation.

For the immune system, LPS represent a maximum-level alarm signal, recognised by TLR-4 receptors on hepatic Kupffer cells. The association between SIBO, NAFLD, and endotoxemia makes clear the central role of gut microbiota in the initiation and progression of metabolic liver disease.

The gut–liver circuit: pathophysiological sequence

GUTDysbiosis → bacterial overgrowth in the ileum → disruption of tight junctions	→	LIVERLPS influx via portal vein → TLR-4 activation on Kupffer cells → inflammatory cytokine cascade
GUTReduced secondary bile acids → further dysbiosis and slowed intestinal transit	↔	LIVERChronic inflammation → poor-quality bile → reduced biliary feedback to the gut
GUTExcessive fermentation, bloating, constipation — symptoms that appear ‘merely digestive’	→	LIVERMitochondrial oxidative stress → hepatocyte triglyceride accumulation → steatosis → fibrosis risk

SIBO is not an infection to be eradicated. It is a signal that the body’s regulation, drainage, and defence architecture has broken down. Until you restore that architecture, no antimicrobial — natural or pharmaceutical — can be the final answer.

The laboratory triangle nobody reads together

There is a blood panel that flies under the radar every day. Three values, read separately, seem unremarkable. Read together, they tell a precise story.

Metabolic alert triangle Mildly elevated GGT — early marker of hepatic oxidative stress and glutathione dysfunction; routinely dismissed as ‘only slightly above range’ ALT in the upper half of normal range — not normal. A value between 30–40 U/L in a patient with chronic bloating and fatigue is an active hepatocellular inflammation signal Elevated uric acid — not just gout. A marker of mitochondrial metabolic stress closely correlated with NAFLD progression This triple pattern + SIBO + constipation + chronic fatigue is not coincidence. It is a coherent diagnostic picture requiring integrated management, not three separate specialists

What Chinese medicine sees — and what gastroenterology alone cannot offer

Traditional Chinese Medicine maps the gut-liver axis through the relationship between  (Liver) and  (Spleen-Stomach). When Liver Qi stagnates — through prolonged stress, dietary overload, or toxic burden — it stops moving the digestive system downward, producing exactly the clinical picture seen in these patients: bloating, slowed transit, inadequate bile, accumulation.

The pattern of  is not poetic metaphor. A multicentre randomised trial of 180 NAFLD patients diagnosed with this TCM pattern compared acupuncture at BL18, LR3, ST40, ST36, and SP6 against standard pharmacotherapy. The acupuncture group showed significantly superior improvement in liver enzymes, TCM syndrome scores, and abdominal ultrasound findings at 6 months.

Integrated TCM perspective: The Liver in Chinese medicine is not merely a detoxification organ — it is the conductor of metabolic flow. When it stagnates, everything slows: digestion, biliary transit, circadian rhythm, sleep, stress response. This is why most patients with SIBO and fatty liver also report irritability, unrefreshing sleep, and occipital tension. These are not separate symptoms. They are the same dysfunction showing up in different places.

Why oregano oil is not a strategy — it’s a shortcut that doesn’t hold

Worth saying clearly, because it is one of the most common mistakes in SIBO self-management, amplified by social media and expensive protocols with months-long waiting lists.

Oregano oil is a powerful, indiscriminate antimicrobial. It knocks down bacterial load — without correcting the terrain that allowed SIBO to establish itself in the first place. The result is a temporary gap that the body fills again, : more mucosal inflammation, increased permeability, an even higher endotoxin load reaching the liver.

The real protocol works on the terrain: intestinal motility, bile quality, hepatic function, mucosal integrity, competitive microbiota. When the terrain no longer allows SIBO to thrive, SIBO disappears — not because it was eradicated, but because it no longer has the conditions to exist.

The integrative protocol — how we work in Milan and Lugano

PHASE 1 — ASSESSMENTComplete diagnostic picture SIBO breath test, hepatic ultrasound, extended metabolic panel (GGT, ALT, AST, uric acid, insulin, HOMA-IR, full lipid profile), TCM energetic pattern evaluation.	PHASE 2 — TERRAINIntestinal barrier & bile flow Hepatoprotective phytotherapy (Silybum marianum, Berberine, Schisandra), biliary support, endotoxic load reduction, personalised anti-inflammatory dietary protocol.
PHASE 3 — REGULATIONAcupuncture & motility Systemic acupuncture cycle for hepatic Qi regulation, improved intestinal motility, systemic inflammation reduction. Key points: LR3, ST36, SP6, GB34, ST25.	PHASE 4 — RECOLONISATIONMicrobiota & maintenance Selective reintroduction of evidence-specific probiotics (B. longum, L. acidophilus, S. thermophilus), monitoring at 3 and 6 months, protocol adjustment to individual responses.

A note on the removed gallbladder

Cholecystectomy is one of the most common surgical procedures in Italy. And one of the most frequently overlooked risk factors for both NAFLD and SIBO in the patient history. Without concentrated, rhythmic bile, fat digestion deteriorates, the microbiota tends toward dysbiosis, and the burden on the liver increases. Many patients develop steatosis years after the procedure without anyone connecting the two events. If you have had a cholecystectomy, this is not secondary information — it is the starting point.

IN-CLINIC OR TELEMEDICINE CONSULTATIONPersonalised integrative assessment — Milan, Lugano, worldwide First consultation available in-clinic in Milan and Lugano, or via telemedicine globally. TCM + functional medicine + clinical naturopathy. No automatic protocols. Book a 20-minute discovery call →

SCIENTIFIC REFERENCES

1. Mouries J, et al. SIBO and NAFLD: What Do We Know in 2023? Nutrients. 2023;15(6):1323. doi:10.3390/nu15061323
2. Miele L, et al. Endotoxins and Non-Alcoholic Fatty Liver Disease. Front Endocrinol. 2021;12:770986.
3. Zhu LR, et al. TCM modulation of gut microbiota for liver disease. Front Immunol. 2023;14:1086078.
4. Chen H, Xu L, Huang F. TCM and NAFLD based on the gut-liver axis. Progress in Pharmaceutical Sciences. 2024;48(11):849-859.
5. Wang X, et al. Acupuncture for insulin resistance and NAFLD. Int J Gen Med. 2024. doi:10.2147/IJGM.S484260
6. Ao Y, et al. Acupuncture safety and efficacy for NAFLD: meta-analysis. Medicine. 2025;104(18):e42272.
7. Liu J, et al. NAFLD Liver Qi Stagnation — multicentre RCT. PubMed 2016. PMID:27348904
8. Riazi K, et al. Global NAFLD prevalence. Clin Mol Hepatol. 2022. doi:10.3350/cmh.2022.0365